October, recognized globally as Breast Cancer Awareness Month, brings renewed focus to the disease that affects millions worldwide. Beyond the symbolic pink ribbons, advances in medical genetics have deepened understanding of breast cancer’s roots, emphasizing its nature as a genetic disease.

Breast cancer arises primarily from genetic alterations, involving mutations in the DNA that regulate cell growth. These mutations can be either somatic—acquired during a person’s lifetime due to aging or environmental influences—or germline, inherited from a biological parent and present in every cell from birth. While most breast cancers are sporadic, caused by somatic mutations, hereditary breast cancer accounts for approximately 5% to 10% of cases. Individuals with inherited pathogenic germline variants carry a substantially increased lifetime risk for breast and ovarian cancers.

Family history remains an important indicator of hereditary risk. A pattern of multiple relatives diagnosed with breast or ovarian cancer, particularly at a young age (under 50), or cases involving male breast cancer, may signal the need for clinical genetic testing. This testing, which can be performed through a simple blood or saliva sample, screens for mutations linked to hereditary cancer syndromes. Early identification of such mutations enables proactive healthcare decisions, including enhanced surveillance through earlier or more frequent breast imaging, such as MRI, and consideration of preventive surgical options.

Among the most well-known genes implicated in hereditary breast cancer are BRCA1 and BRCA2. These tumor suppressor genes play a critical role in DNA repair, and pathogenic variants can increase breast cancer risk significantly, with some studies estimating lifetime risks of around 70% or higher. Genetic panels have expanded to include additional genes such as PALB2, which partners with BRCA2 to repair DNA; TP53, mutations of which cause Li-Fraumeni syndrome and elevate risk for early-onset breast cancer and other cancers; and moderate-risk genes like CHEK2 and ATM, which affect DNA damage response pathways but confer varying degrees of risk depending on specific mutations and individual factors.

The biology of breast tumors is further characterized by the presence or absence of hormone receptors and growth factor proteins. Estrogen receptors (ER) and progesterone receptors (PR) can promote tumor growth when present, allowing the use of hormone therapies such as Tamoxifen, which blocks estrogen receptor signaling, or aromatase inhibitors, which reduce estrogen production. Another key protein is HER2 (Human Epidermal Growth Factor Receptor 2); tumors overexpressing HER2 tend to be more aggressive but may respond to targeted therapies like Trastuzumab (Herceptin).

Tumors lacking ER, PR, and HER2 receptors—referred to as triple-negative breast cancer (TNBC)—do not respond to hormone or HER2-targeted treatments. Management of TNBC often involves chemotherapy, and in some cases, immunotherapy or other targeted approaches based on tumor characteristics.

Experts emphasize the importance of early detection and informed decision-making as essential components in improving breast cancer outcomes. Routine mammograms and clinical screenings can detect breast changes before physical symptoms develop. For those with significant family histories, consulting genetic counselors can offer critical guidance tailored to individual risk.

In sum, the intersection of genetics, molecular biology, and personalized medicine is reshaping breast cancer care, underscoring that knowledge and early intervention are key tools in reducing mortality and improving quality of life.